Specifically, clinical trials have demonstrated that forms of RS2 promote metabolic benefits, including increases in glucagon-like peptide-1 (GLP-1) [13,19,20,21], decreases in circulating insulin and insulin resistance [22,23,24,25,26], attenuating fasting glucose levels [26,27,28,29], and weight loss [13,30]. The gene discussed is INS; the disease is Insulin resistance.